
Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter. ADMA Biologics collected $26.38 million in revenue during Q4, but reported earnings showed a $16.65 million loss.